Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07219511 · ClinicalTrials.gov registry record · Phase 1

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart, sponsored by Vasa Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
42
Enrollment target
17
Study locations

NCT07219511: Recruiting Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart, sponsored by Vasa Therapeutics.

NCT07219511 is a Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart that is actively recruiting participants, run by Vasa Therapeutics. The registered enrollment target is 42 participants, below the 215-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (80% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07219511, a Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) and Heart, is actively recruiting participants, sponsored by Vasa Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
42 participants
Enrollment target
17
Study locations

Study Summary

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

Primary Outcome

To evaluate the safety and tolerability of VS-041 in participants with HFpEF

Conditions Studied

Heart Failure With Preserved Ejection Fraction (HFPEF) Heart

Interventions

  • OTHER Placebo
  • DRUG VS-041

Study Locations (17)

California

  • National Institute of Clinical Research - Huntington Beach
  • FOMAT - Santa Maria
  • Invivocure LLC - Van Nuys

Florida

  • New Generation of Medical Research - Hialeah
  • Jacksonville Center for Clinical Research - Jacksonville
  • Amavita Health - North Miami Beach

Illinois

  • Chicago Medical Research - Hazel Crest
  • Methodist Medical Center of Illinois - Peoria

Arkansas

  • Cardiology and Medicine Clinic - Little Rock

Louisiana

  • Louisiana Heart Center - Slidell

Missouri

  • Washington University - St Louis

New Jersey

  • Ash Research Clinic - Brick

New York

  • Erie County Medical Center - Buffalo

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2025-11-04
Est. Completion 2026-07
Phase Phase 1
Vasa Therapeutics

1 total trials

What NCT07219511 shows while recruiting

NCT07219511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 215-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (80% lower).

The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction (HFPEF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07219511 lists 17 locations in 12 states (California, Florida, Illinois).

Frequently Asked Questions

What is clinical trial NCT07219511 about?

NCT07219511 is a clinical study titled "A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)". A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)

What is the current status of trial NCT07219511?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-11-04. Estimated completion is 2026-07.

What conditions does trial NCT07219511 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFPEF), Heart.

What interventions are being tested in trial NCT07219511?

The interventions under investigation include: Placebo (OTHER), VS-041 (DRUG).

Who is sponsoring clinical trial NCT07219511?

This trial is sponsored by Vasa Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07219511 being conducted?

This trial has 17 study locations across Arkansas, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction (HFPEF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07219511's enrollment target sits among peer trials

42 8th of 9 higher than 2 of 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction (HFPEF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07219511

Source: ClinicalTrials.gov NCT07219511, the US trial registry maintained by the National Library of Medicine. NCT07219511 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.